NASDAQ:KINKindred Biosciences Stock Price, Forecast & News

Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KIN shares have decreased by 41.9% and is now trading at $4.70. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kindred Biosciences.

Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Kindred Biosciences.

Kindred Biosciences Inc (NASDAQ:KIN) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.04. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to analysts' expectations of $1.75 million. Kindred Biosciences had a negative net margin of 1,567.56% and a negative return on equity of 72.77%. View Kindred Biosciences' earnings history.

7 brokerages have issued 1-year price targets for Kindred Biosciences' stock. Their forecasts range from $8.50 to $13.00. On average, they expect Kindred Biosciences' stock price to reach $10.88 in the next twelve months. This suggests a possible upside of 131.4% from the stock's current price. View analysts' price targets for Kindred Biosciences.

News coverage about KIN stock has been trending neutral recently, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kindred Biosciences earned a news impact score of 0.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutKindred Biosciences.

Kindred Biosciences saw a decrease in short interest in May. As of May 15th, there was short interest totaling 383,500 shares, a decrease of 12.3% from the April 30th total of 437,100 shares. Based on an average daily volume of 220,200 shares, the short-interest ratio is currently 1.7 days. Approximately 1.0% of the shares of the stock are short sold. View Kindred Biosciences' Current Options Chain.

Some companies that are related to Kindred Biosciences include Kala Pharmaceuticals (KALA), Kura Oncology (KURA), Cara Therapeutics (CARA), NextCure (NXTC), Homology Medicines (FIXX), Morphic (MORF), Provention Bio (PRVB), Kadmon (KDMN), Akero Therapeutics (AKRO), G1 Therapeutics (GTHX), Molecular Templates (MTEM), Retrophin (RTRX), Collegium Pharmaceutical (COLL), Arcturus Therapeutics (ARCT) and Eagle Pharmaceuticals (EGRX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), TherapeuticsMD (TXMD) and Cara Therapeutics (CARA).

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.27%), Morgan Stanley (4.41%), Morgan Stanley (4.41%), Granahan Investment Management Inc. MA (2.34%), State Street Corp (1.76%) and Geode Capital Management LLC (1.37%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View institutional ownership trends for Kindred Biosciences.

KIN stock was sold by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Parametric Portfolio Associates LLC, UBS Group AG, WINTON GROUP Ltd, Morgan Stanley, Morgan Stanley, State Street Corp, and Wells Fargo & Company MN. View insider buying and selling activity for Kindred Biosciences.

KIN stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Granahan Investment Management Inc. MA, Geode Capital Management LLC, Cambridge Investment Research Advisors Inc., Deutsche Bank AG, New York State Common Retirement Fund, Bank of New York Mellon Corp, and Nuveen Asset Management LLC. View insider buying and selling activity for Kindred Biosciences.

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $4.70.

Kindred Biosciences has a market capitalization of $184.66 million and generates $4.26 million in revenue each year. The biopharmaceutical company earns $-61,390,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.

The official website for Kindred Biosciences is kindredbio.com.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]